Speaker
Dr
Ulli Köster
(Institut Laue Langevin)
Description
Today a variety of radioisotopes for nuclear medicine applications is available commercially. Still, for some nuclear medicine applications it would be advantageous to use "new" radioisotopes with better decay properties or radioisotopes with higher "quality" (such as high specific activity or non-carrier added quality). When these are not commercially available, or easily producible with in-house means at small cyclotrons, it may hinder promising research directions.
Methods are discussed to overcome this particular type of "isotope shortage" by production using high-flux reactors, spallation by high-energy protons, reactions with heavy ion beams, mass separation or other "unconventional" methods.
Synergies with existing and upcoming RIB facilities are outlined.
Primary author
Dr
Ulli Köster
(Institut Laue Langevin)
